Journal
EXPERT OPINION ON THERAPEUTIC TARGETS
Volume 13, Issue 5, Pages 541-550Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14728220902882130
Keywords
chronic renal failure; dialysis; metalloproteinase; nephroprotection; statins
Categories
Ask authors/readers for more resources
Background: The combination of increased cardiovascular mortality and vascular complications due to dyslipidaemia in chronic kidney disease (CKD) has focused attention onto the potential beneficial effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA) inhibitors (statins) on the course of CKD. Objective: To examine the use of statins in CKD. Methods: A review of relevant literature. Results/conclusion: Current evidence from clinical trials in CKD patients on maintenance dialysis is limited. Therefore, the routine use of statins in this population remains the decision of individual physicians in discussion with their patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available